Increasing Incidence Of Oral Cancers Worldwide Is Propelling The Growth Of The Dysphagia Management Market
Dysphagia, defined as difficulty in initiating, sustaining, and finishing normal swallowing, affects approximately 13% of the population. Dysphagia is classified into two main categories: functional dysphagia and non-fatal dysphagia. People with functional dysphagia have problems initiating and completing certain movements of the upper airway; they rarely have problems with breathing. Non-fatal dysphagia causes problems with breathing and the release of excessive saliva (salivary colic) which can cause the tongue to stick out. These patients typically have no or little pain when the tongue is sticking out but often experience mild to moderate soreness afterward.
The
growing prevalence of oral cancer around the globe is driving the growth of the
dysphagia management market. According to the World Health Organization, there
are an estimated 657,000 new cases of cancers of the oral cavity and
pharynx each year, and more than
330,000 deaths. Dysphagia is associated with the difficulties of swallowing in patient.
It is more common in the geriatric population. The growth of the dysphagia
management market is also attributed to the increasing geriatric population
around the globe. According to the same source, between 2015 and 2050, the
proportion of the world's population over 60 years will nearly double from 12%
to 22%. By 2020, the number of people aged 60 years and older will outnumber
children younger than 5 years. In 2050, 80% of older people will be living in
low- and middle-income countries.
North
America is projected to gain significant growth over the forecast period and
this is attributed to the increasing spending on the healthcare sector by the
regional government. According to the U.S. Centers for Medicare & Medicaid
Services, the U.S. health care spending grew 4.6 percent in 2019, reaching $3.8
trillion or $11,582 per person. As a
share of the nation's Gross Domestic Product, health spending accounted for
17.7 percent.
Key Developments:
1. In October 2019, Sun
Pharmaceutical Industries Ltd. has announced the launch of Drizalma Sprinkle™
(duloxetine delayed-release capsules) in the U.S. for oral use
2. In January 2020, Phagenesis Ltd.
has announced that the company has received Breakthrough Device Designation
from the U.S. Food and Drug Administration (FDA) for its Phagenyx System.
3. In December 2018, Gensco® Pharma,
a specialty pharmaceutical manufacturer specializing in development and
commercialization of prescription transdermal products, announced the execution
of a definitive licensing, development, and supply agreement (the “Agreement”)
with IntelGenx Corp oral drug Delivery Company
Comments
Post a Comment